CytoDyn Shares Outstanding 2012-2025 | CYDY

CytoDyn shares outstanding from 2012 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
CytoDyn Annual Shares Outstanding
(Millions of Shares)
2025 1,243
2024 970
2023 837
2022 677
2021 588
2020 421
2019 272
2018 175
2017 138
2016 95
2015 58
2014 47
2013 30
2012 25
2011 21
CytoDyn Quarterly Shares Outstanding
(Millions of Shares)
2025-11-30 1,261
2025-08-31 1,253
2025-05-31 1,243
2025-02-28 1,228
2024-11-30 1,221
2024-08-31 1,198
2024-05-31 970
2024-02-29 982
2023-11-30 959
2023-08-31 924
2023-05-31 837
2023-02-28 832
2022-11-30 813
2022-08-31 788
2022-05-31 677
2022-02-28 696
2021-11-30 663
2021-08-31 633
2021-05-31 588
2021-02-28 578
2020-11-30 578
2020-08-31 556
2020-05-31 421
2020-02-29 432
2019-11-30 389
2019-08-31 365
2019-05-31 272
2019-02-28 296
2018-11-30 259
2018-08-31 219
2018-05-31 175
2018-02-28 178
2017-11-30 158
2017-08-31 152
2017-05-31 138
2017-02-28 142
2016-11-30 136
2016-08-31 124
2016-05-31 95
2016-02-29 105
2015-11-30 84
2015-08-31 72
2015-05-31 58
2015-02-28 59
2014-11-30 56
2014-08-31 56
2014-05-31 47
2014-02-28 55
2013-11-30 45
2013-08-31 31
2013-05-31 30
2013-02-28 30
2012-11-30 30
2012-08-31 29
2012-05-31 25
2012-02-29 25
2011-11-30 22
2011-08-31 22
2011-05-31 21
2011-02-28 22
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.310B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $100.311B 35.03
Takeda Pharmaceutical (TAK) Japan $58.739B 11.54
Zoetis (ZTS) United States $53.462B 19.73
BeOne Medicines - (ONC) Switzerland $37.951B 201.20
Sandoz Group AG (SDZNY) Switzerland $37.721B 0.00
Otsuka Holdings, - (OTSKY) $37.221B 0.00
Daiichi Sankyo, - (DSNKY) Japan $36.542B 0.00
United Therapeutics (UTHR) United States $20.394B 17.95
Shionogi (SGIOY) Japan $19.736B 15.26
Merck (MKKGY) Germany $19.561B 12.06
IPSEN (IPSEY) France $15.077B 0.00
Ionis Pharmaceuticals (IONS) United States $13.055B 0.00
Neurocrine Biosciences (NBIX) United States $12.457B 26.92
Summit Therapeutics (SMMT) United States $11.536B 0.00
Orion OYJ (ORINY) Finland $11.214B 19.47
Madrigal Pharmaceuticals (MDGL) United States $10.554B 0.00
Eisai (ESAIY) $9.636B 0.00
Ono Pharmaceutical (OPHLF) Japan $8.769B 20.98
Stevanato Group S.p.A (STVN) Italy $4.849B 27.14
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.828B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.659B 22.12
Crinetics Pharmaceuticals (CRNX) United States $4.363B 0.00
Indivior Pharmaceuticals (INDV) United States $4.323B 17.64
Corcept Therapeutics (CORT) United States $4.204B 45.42
NewAmsterdam Pharma (NAMS) Netherlands $3.927B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.322B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.990B 9.54
Hypermarcas (HYPMY) Brazil $2.658B 18.24
Dyne Therapeutics (DYN) United States $2.220B 0.00
Guardian Pharmacy Services (GRDN) United States $2.119B 40.81
Avadel Pharmaceuticals (AVDL) Ireland $2.113B 0.00
Soleno Therapeutics (SLNO) United States $2.000B 0.00
Ocular Therapeutix (OCUL) United States $1.933B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.876B 22.23
Harrow (HROW) United States $1.766B 108.39
Ardelyx (ARDX) United States $1.669B 0.00
Enliven Therapeutics (ELVN) United States $1.586B 0.00
Oruka Therapeutics (ORKA) United States $1.559B 0.00
Definium Therapeutics (DFTX) United States $1.552B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.551B 0.00
Relay Therapeutics (RLAY) United States $1.548B 0.00
Nektar Therapeutics (NKTR) United States $1.451B 0.00
Collegium Pharmaceutical (COLL) United States $1.447B 7.17
BioCryst Pharmaceuticals (BCRX) United States $1.425B 84.50
Evotec AG (EVO) Germany $1.248B 0.00
Savara (SVRA) United States $1.139B 0.00
Xeris Biopharma Holdings (XERS) United States $1.132B 0.00
Theravance Biopharma (TBPH) United States $0.990B 41.55
Cronos Group (CRON) Canada $0.988B 0.00
Aktis Oncology (AKTS) United States $0.900B 0.00
ARS Pharmaceuticals (SPRY) United States $0.875B 0.00
Xencor (XNCR) United States $0.828B 0.00
Esperion Therapeutics (ESPR) United States $0.820B 0.00
KalVista Pharmaceuticals (KALV) United States $0.754B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.732B 17.31
Bioventus (BVS) United States $0.684B 14.02
Rigel Pharmaceuticals (RIGL) United States $0.623B 5.56
ProKidney (PROK) United States $0.596B 0.00
Lyell Immunopharma (LYEL) United States $0.549B 0.00
4D Molecular Therapeutics (FDMT) United States $0.534B 0.00
Altimmune (ALT) United States $0.511B 0.00
Siga Technologies (SIGA) United States $0.486B 6.66
Zevra Therapeutics (ZVRA) United States $0.479B 0.00
Elite Pharmaceuticals (ELTP) United States $0.474B 0.00
Organogenesis (ORGO) United States $0.473B 0.00
Nature's Sunshine Products (NATR) United States $0.471B 28.03
Lexeo Therapeutics (LXEO) United States $0.461B 0.00
Aquestive Therapeutics (AQST) United States $0.445B 0.00
USANA Health Sciences (USNA) United States $0.382B 10.66
Aclaris Therapeutics (ACRS) United States $0.346B 0.00
Protara Therapeutics (TARA) United States $0.336B 0.00
Akebia Therapeutics (AKBA) United States $0.321B 0.00
Aldeyra Therapeutics (ALDX) United States $0.318B 0.00
Cybin (HELP) Canada $0.304B 0.00
Relmada Therapeutics (RLMD) United States $0.273B 0.00
Minerva Neurosciences (NERV) United States $0.271B 0.00
Avalo Therapeutics (AVTX) United States $0.264B 0.00
Enlivex Therapeutics (ENLV) Israel $0.263B 0.00
Larimar Therapeutics (LRMR) United States $0.261B 0.00
Journey Medical (DERM) United States $0.257B 0.00
OmniAb (OABI) United States $0.245B 0.00
Profound Medical (PROF) Canada $0.240B 0.00
Achieve Life Sciences (ACHV) Canada $0.224B 0.00
MediWound (MDWD) Israel $0.222B 0.00
Context Therapeutics (CNTX) United States $0.211B 0.00
Heron Therapeutics (HRTX) United States $0.211B 0.00
Silence Therapeutics (SLN) United Kingdom $0.210B 0.00
Surrozen (SRZN) United States $0.210B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.184B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.178B 0.00
AleAnna (ANNA) United States $0.171B 0.00
Karyopharm Therapeutics (KPTI) United States $0.157B 0.00
Century Therapeutics (IPSC) United States $0.153B 0.00
Prelude Therapeutics (PRLD) United States $0.140B 0.00
VAXART, INC (VXRT) United States $0.136B 0.00
Unicycive Therapeutics (UNCY) United States $0.133B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.133B 0.00
Avita Medical (RCEL) United States $0.127B 0.00
Inhibikase Therapeutics (IKT) United States $0.126B 0.00
Cardiol Therapeutics (CRDL) Canada $0.116B 0.00
Korro Bio (KRRO) United States $0.105B 0.00
Cassava Sciences (SAVA) United States $0.101B 0.00
Incannex Healthcare (IXHL) Australia $0.093B 0.00
Vivani Medical (VANI) United States $0.092B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.084B 35.76
Pyxis Oncology (PYXS) United States $0.081B 0.00
Assertio Holdings (ASRT) United States $0.079B 0.00
PolyPid (PYPD) Israel $0.070B 0.00
Gain Therapeutics (GANX) United States $0.070B 0.00
HST Global (HSTC) United States $0.069B 0.00
Rafael Holdings (RFL) United States $0.062B 0.00
PMV Pharmaceuticals (PMVP) United States $0.059B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.058B 48.50
Fractyl Health (GUTS) United States $0.057B 0.00
BioNxt Solutions (BNXTF) Canada $0.057B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.056B 0.00
Dominari Holdings (DOMH) United States $0.055B 0.00
NRx Pharmaceuticals (NRXP) United States $0.053B 0.00
Acrivon Therapeutics (ACRV) United States $0.051B 0.00
Nutriband (NTRB) United States $0.050B 0.00
Lipocine (LPCN) United States $0.048B 0.00
ElectroCore (ECOR) United States $0.043B 0.00
Lite Strategy (LITS) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Plus Therapeutics (PSTV) United States $0.038B 0.00
Talphera (TLPH) United States $0.038B 0.00
Telomir Pharmaceuticals (TELO) United States $0.037B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
SCYNEXIS (SCYX) United States $0.031B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.030B 0.00
TherapeuticsMD (TXMD) United States $0.027B 0.00
Wellgistics Health (WGRX) United States $0.025B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.024B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
Jupiter Neurosciences (JUNS) United States $0.020B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Phio Pharmaceuticals (PHIO) United States $0.018B 0.00
Scienture Holdings (SCNX) United States $0.018B 0.00
Klotho Neurosciences (KLTO) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
Traws Pharma (TRAW) United States $0.015B 0.02
Iterum Therapeutics (ITRM) Ireland $0.015B 0.00
Vyome Holdings (HIND) United States $0.015B 0.00
Cosmos Health (COSM) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Liminatus Pharma (LIMN) United States $0.012B 0.00
Tempest Therapeutics (TPST) United States $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.010B 0.00
Inotiv (NOTV) United States $0.010B 0.00
BioVie (BIVI) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Ainos (AIMD) United States $0.007B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.007B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
Redhill Biopharma (RDHL) Israel $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Indaptus Therapeutics (INDP) United States $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Ernexa Therapeutics (ERNA) United States $0.003B 0.00
China SXT Pharmaceuticals (SXTC) China $0.003B 0.00
Lyra Therapeutics (LYRA) United States $0.002B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
PainReform (PRFX) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00